RxDoctor Payments Data

Gagandeep Joshi, MD

Cardiovascular Disease · Marietta, GANPI 1851618565

Payments from drug & device makers

$3,812in general payments, 2019–2025

Across 83 payments — averaging $45.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Abiomed$746
  • Pfizer$255
  • Esperion Therapeutics, Inc.$224
  • Amgen$172
  • Novartis$165
  • plus $999 from 16 others

What the payments were for

  • Travel & lodging$72419%
  • Food & beverage$1,90050%
  • Education$1,18831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,812 in reported general payments places this provider in the 55th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$174,092
Medicare patients
2,051
Services billed
3,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$259,047
XareltoRivaroxaban92$77,321
JardianceEmpagliflozin51$65,024
EntrestoSacubitril/Valsartan58$60,551
Repatha SureclickEvolocumab56$56,845
Repatha SyringeEvolocumab32$31,101
FarxigaDapagliflozin Propanediol34$28,565
BrilintaTicagrelor13$11,971
Rosuvastatin Calcium475$6,137
Ezetimibe232$5,104
Atorvastatin Calcium426$3,401
Metoprolol Succinate221$3,074
Nifedipine ErNifedipine72$2,373
Ranolazine ErRanolazine16$1,841
Losartan Potassium161$1,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$255$259,047218 claims
Johnson & JohnsonXarelto$97$77,32192 claims
Boehringer IngelheimJardiance$25$65,02451 claims
NovartisEntresto$165$60,55158 claims
AstraZenecaFarxiga, Brilinta$1,253$40,53647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →